The Global Ibogaine Therapy Alliance (GITA) is a nonprofit organization dedicated to advancing the responsible, evidence-based use of ibogaine through clinical guidelines, provider training, harm reduction, and international policy engagement. Founded in 2012, GITA currently serves as one of the primary bodies working to standardize ibogaine treatment globally — a critical function given the compound's complex safety profile and inconsistent legal status across jurisdictions.

What Is the Global Ibogaine Therapy Alliance and How Did It Form?

GITA emerged from a coalition of clinicians, researchers, harm reduction advocates, and treatment providers who recognized that ibogaine was being administered in widely varying — and sometimes dangerous — conditions around the world. With no regulatory framework governing ibogaine clinics in countries where it is legal, early providers operated with little standardization in screening, dosing, or cardiac monitoring protocols.

The organization formally incorporated to fill that vacuum. Its founding members included figures from the psychedelic research community, addiction medicine, and anthropology, reflecting ibogaine's dual identity as both a pharmacological intervention and a ceremonial plant medicine with deep roots in the Bwiti tradition of Central Africa. GITA's structure acknowledges both dimensions while keeping clinical safety at its core.

What Clinical Guidelines Has GITA Published?

GITA published its landmark Clinical Guidelines for Ibogaine-Assisted Detoxification in 2015. These guidelines represent a consensus document built from available peer-reviewed literature, provider experience, and harm reduction principles. Key components include:

  • Pre-treatment cardiac screening: A 12-lead electrocardiogram (ECG) to identify QTc prolongation, a primary cardiac risk factor with ibogaine. The guidelines recommend excluding patients whose corrected QT interval exceeds 450–470 ms.
  • Medical history requirements: Screening for liver disease, seizure disorders, and psychiatric contraindications including active psychosis.
  • Drug interaction protocols: Identifying medications that prolong the QT interval or are metabolized via CYP2D6 and CYP3A4 pathways, which ibogaine significantly affects.
  • Dosing frameworks: Guidance on test doses, flood doses, and booster doses calibrated by body weight and clinical context.
  • Post-treatment monitoring: Minimum observation periods and criteria for safe discharge, including cardiac telemetry recommendations.

These guidelines do not carry regulatory force, but they are widely referenced by clinic operators, harm reduction organizations, and researchers as a de facto standard of care.

Safety Note: Ibogaine carries documented cardiac risks, including QTc prolongation and potentially fatal arrhythmias. Fatalities have been reported in treatment settings, often associated with inadequate pre-screening or drug interactions. GITA's guidelines exist precisely because these risks are preventable with proper protocols. Anyone researching ibogaine treatment should verify that any provider follows comprehensive cardiac screening practices.

How Does GITA Support Provider Training and Accreditation?

Beyond publishing guidelines, GITA has developed training programs and convenes annual international conferences that bring together providers, researchers, and policymakers. These gatherings function as continuing education forums and community-building events, helping to create a professional culture around ibogaine practice where none previously existed.

GITA has also worked toward a provider accreditation framework — a process by which clinics and practitioners can demonstrate adherence to published safety standards. This is particularly significant because ibogaine treatment currently operates in a legal gray zone in many countries and is entirely unregulated in several where it is technically permitted. Voluntary accreditation creates accountability in the absence of government oversight.

Training curricula typically cover pharmacology, contraindication assessment, cardiac monitoring, integration support, and cultural competency regarding the Bwiti origins of ibogaine use — an element GITA considers ethically important given ongoing concerns about the appropriation of indigenous knowledge.

What Policy and Advocacy Work Does GITA Undertake?

GITA engages with policymakers in multiple jurisdictions to advocate for regulatory pathways that would allow ibogaine to be studied and administered under appropriate medical supervision. This includes engagement with the U.S. Food and Drug Administration, where ibogaine currently holds Schedule I status under the Controlled Substances Act — meaning it is classified as having no accepted medical use and a high potential for abuse. Rescheduling or creating a research exemption pathway would require either FDA approval of an ibogaine-based drug or a DEA scheduling action.

Research has been accelerating. A landmark 2024 study published in Nature Medicine by Cherian et al. examined magnesium-ibogaine therapy in U.S. special operations veterans with traumatic brain injuries, finding significant reductions in PTSD, depression, and anxiety symptoms. This type of peer-reviewed clinical data strengthens GITA's advocacy arguments that controlled research access is medically justified.

GITA also monitors and responds to international regulatory developments. New Zealand has allowed ibogaine use in supervised clinical settings. Several European nations tolerate regulated administration. Mexico and other Latin American countries host legal clinics operating under varying frameworks. GITA's policy work helps create a shared evidentiary base that regulators in multiple countries can reference.

How Does GITA Address Harm Reduction for People Seeking Treatment Now?

Because ibogaine remains Schedule I in the United States, many people who want treatment travel abroad to legal clinics — a phenomenon sometimes called "medical tourism." GITA's harm reduction function here is practical: helping prospective patients understand what questions to ask providers, what safety standards to expect, and what red flags suggest an unsafe operation.

GITA publishes resources explaining minimum safety requirements and maintains connections to the provider community that allows it to informally vet clinic standards. The organization is careful to note that it does not formally endorse specific clinics, recognizing that standards can change and that its role is educational rather than referral-based.

For researchers and journalists, GITA maintains a network of experts who can speak to clinical, cultural, and policy dimensions of ibogaine — an important function as media and scientific interest in psychedelic medicine has grown significantly over recent years.

What Is GITA's Relationship to the Broader Psychedelic Medicine Movement?

GITA occupies a distinct position within the wider psychedelic medicine landscape. Unlike organizations primarily focused on psilocybin or MDMA — compounds that have advanced further in FDA clinical trials — GITA addresses a substance with a more complex safety and regulatory profile. Ibogaine's cardiac risks require a higher threshold of medical infrastructure than most other psychedelic compounds, making the standardization work GITA does especially consequential.

GITA collaborates with organizations like MAPS (Multidisciplinary Association for Psychedelic Studies), academic research centers, and harm reduction networks, while maintaining a specific focus on ibogaine's unique clinical and cultural context. The organization has consistently emphasized that ibogaine should not simply be folded into generic "psychedelic therapy" frameworks but requires protocols tailored to its distinct pharmacology and risks.

Frequently Asked Questions

No. GITA is a nonprofit advocacy and standards organization, not a government agency. It has no legal authority to license or certify clinics. Its guidelines are voluntary, though they are widely used as a reference standard by providers, researchers, and harm reduction organizations. Actual clinic regulation depends on the laws of the country in which a clinic operates.
GITA does not formally endorse or recommend individual clinics. Their published materials can help you understand what safety standards to look for in any provider. Questions about cardiac screening protocols, staff medical credentials, and emergency response capacity are all areas their guidelines address. Independent research and consultation with a medical professional familiar with ibogaine are always advisable before pursuing treatment.
GITA's foundational Clinical Guidelines for Ibogaine-Assisted Detoxification were published in 2015. The organization periodically revisits these documents as new clinical evidence emerges. Given the volume of research published in recent years — including data from veteran studies and observational outcome trials — GITA has been engaged in updating and refining its guidance to reflect current evidence.
Ibogaine is a Schedule I controlled substance under the U.S. Controlled Substances Act, meaning it is illegal to possess, administer, or distribute outside of DEA-authorized research. GITA is a U.S.-incorporated nonprofit and conducts its advocacy, research support, and educational work legally. It does not facilitate or encourage any illegal activity, and it advocates for regulatory pathways that would allow ibogaine to be studied and used therapeutically under appropriate legal frameworks.
GITA's guidelines focus heavily on QTc interval prolongation, which can lead to a dangerous arrhythmia called torsades de pointes. They recommend pre-treatment ECGs, exclusion criteria based on QTc thresholds, and continuous cardiac monitoring during treatment. Drug interactions — particularly with methadone, certain antidepressants, and other QT-prolonging medications — are identified as major risk factors requiring careful management or treatment contraindication.
Yes. GITA explicitly acknowledges ibogaine's origins in the Bwiti spiritual tradition of Gabon and Cameroon, where the iboga plant has been used ceremonially for generations. The organization incorporates cultural competency into its provider training, addressing ethical concerns about benefit-sharing, appropriation, and the rights of indigenous communities. This distinguishes GITA's framework from purely biomedical approaches and reflects a broader commitment to ethical practice.
Congressional interest in ibogaine has grown, particularly regarding its potential for treating opioid use disorder and PTSD in military veterans. Bills have been introduced in recent sessions to fund ibogaine research, and the 2024 National Defense Authorization Act included language directing the Department of Defense to study ibogaine for veteran care. GITA's published guidelines and its network of clinical experts inform these legislative conversations, providing a technical foundation for policymakers evaluating ibogaine's risks and potential benefits.

If you are researching ibogaine treatment — whether for yourself, a family member, or professional purposes — the Global Ibogaine Therapy Alliance's published guidelines and public resources are a valuable starting point for understanding what responsible practice looks like. Because ibogaine carries meaningful medical risks and remains Schedule I in the United States, engaging with a physician experienced in addiction medicine or psychedelic medicine before making any treatment decisions is strongly advised. An independent medical evaluation can help you assess whether ibogaine treatment is appropriate given your individual health history, and can help you identify what safety protocols any prospective provider should be able to demonstrate.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.